Poor sleep quality is associated with exercise limitation in precapillary pulmonary hypertension by Henning Tiede et al.
Tiede et al. BMC Pulmonary Medicine  (2015) 15:11 
DOI 10.1186/s12890-015-0005-3RESEARCH ARTICLE Open AccessPoor sleep quality is associated with exercise
limitation in precapillary pulmonary hypertension
Henning Tiede1, Janet Rorzyczka1, Rio Dumitrascu1, Michael Belly1, Frank Reichenberger2, Hossein Ardeschir Ghofrani1,
Werner Seeger1, Jörg Heitmann1 and Richard Schulz1*Abstract
Background: Patients with precapillary pulmonary hypertension (PH) have been reported to suffer from poor sleep
quality, however, if this is related to physical exercise performance has not yet been thoroughly investigated.
Methods: Clinically stable out-patients with idiopathic pulmonary arterial hypertension (IPAH, n = 52) and chronic
thromboembolic PH (CTEPH, n = 64) in NYHA classes II and III were prospectively enrolled. 54 healthy volunteers
matched for anthropometric variables served as a control group. The Pittsburgh Sleep Quality Index (PSQI) was
used to rate subjective sleep quality. In the PH patients, six-minute walk tests (6MWT) were performed to assess
exercise capacity.
Results: Poor sleep quality (i.e. a PSQI score > 5) occurred more frequently in PH (IPAH: n = 25 [48.1%], CTEPH:
n = 39 [60.9%], controls: n = 10 [18.5%]; p < 0.01 when compared to controls). In addition, poor vs. good sleepers
had significantly higher average NYHA class (IPAH: 2.6 ± 0.1 vs. 2.3 ± 0.1, CTEPH: 2.8 ± 0.1 vs. 2.3 ± 0.2; p < 0.01) and
shorter 6MWT distances (IPAH: 338 ± 23 vs. 441 ± 29 m, CTEPH: 355 ± 15 vs. 413 ± 26 m; p < 0.05).
Conclusions: Self-reported poor sleep quality is more common in PH than in healthy controls. Furthermore, it is
related to reduced physical exercise capacity.
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It is well known that fatigue is a prominent clinical fea-
ture of precapillary pulmonary hypertension (PH, [1]).
This may be considered to be due to right heart failure,
however, it could also be the consequence of sleep dis-
turbances occurring in these patients. In this context,
significant proportions of PH patients have been found
to suffer from night-time hypoxemia and sleep apnea
[2-6]. Furthermore, mood disorders such as anxiety and
depression which occur at higher frequencies in PH may
lead to problems with falling asleep and/or maintaining
normal sleep [7]. Finally, the restless legs syndrome has
also been reported to be prevalent in PH [8].
In line with these assumptions, a recent study by Batal
& colleagues reported poor sleep quality as assessed by
the Pittsburgh Sleep Quality Index (PSQI) in 29 out of* Correspondence: Richard.Schulz@innere.med.uni-giessen.de
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unless otherwise stated.40 patients with PH. Furthermore, correlations with
depression, dyspnea and reduced quality of life were
described [9]. However, apart from the relatively low
number of patients, this study had some other limita-
tions. First, the authors did not include a control group
without PH. Second, the patients had a mix of etiolo-
gies leading to PH thus making it difficult to ascribe
the findings to the presence of PH by itself.
Therefore, we aimed to evaluate sleep quality in a larger
patient cohort with PH unbiased by any other underlying
disorder and to compare it to a healthy control group
matched for anthropometric variables. Furthermore, we
looked for patient characteristics linked to the presence of
poor sleep quality in PH. In particular, we wanted to test
the hypothesis that those patients who are poor sleepers
have more advanced disease and/or reduced physical exer-
cise capacity.
For this purpose, we recruited patients with an ascer-
tained diagnosis of idiopathic pulmonary arterial hyper-
tension (IPAH) or chronic thromboembolic PH (CTEPH)his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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standard sleep questionnaires.
Methods
Patient recruitment and assessment
The patients of the present study were investigated dur-
ing an ambulatory visit to the pulmonary hypertension
unit of the University of Giessen Lung Center, Germany
between March and September 2012. The main inclu-
sion criterion was the presence of PH as verified by right
heart catheterisation performed within the preceding six
months (mean pulmonary artery pressure [PAP] at rest
of ≥ 25 mm Hg, pulmonary capillary wedge pressure
[PCWP] < 15 mm Hg). Furthermore, the patients had to
suffer from IPAH or CTEPH as determined by a diag-
nostic work-up including among others chest CT scans
and ventilation/perfusion scintigraphy. Finally, they were
requested to be clinically stable in New York Heart As-
sociation (NYHA) functional classes II or III. Exclusion
criteria were the following : clinical signs of decompen-
sated right heart failure (i.e. leg edema, syncope), known
sleep-disorders such as sleep apnea, major neuropsychi-
atric diseases and intake of drugs interfering with central
nervous system activity (for example benzodiazepines).
The anthropometric parameters of the patients were
determined, i.e. age, sex and body mass index (BMI). All
patients had pulmonary function tests with blood gas
analysis from arterialized ear lobes.
The NYHA class was determined and six-minute walk
tests (6MWT) were performed according to standard
protocols [10]. Furthermore, serum brain natriuretic
peptide (BNP) levels were measured. Finally, the intake
of medications was evaluated, i.e. PH-specific therapy
(phosphodiesterase-5-inhibitors, endothelin receptor an-
tagonists, prostacyclin analogues), diuretics and oral an-
ticoagulants and it was noted whether the patients were
on long-term oxygen therapy (LTOT). Healthy volun-
teers matched with the PH patients for age, sex and BMI
served as controls. They were recruited among the rela-
tives and friends of one of the authors (R.D.). Based on
their medical history, they were judged to be free of any
chronic illness. In particular, PH was deemed to be ab-
sent (i.e. they did not suffer from symptoms suggestive
of the disease such as exertional dyspnea, leg edema or
syncope). The study protocol had been approved by
the ethics committee of the medical faculty of the
Justus-Liebig-University Giessen (approval number:
20/12) and all patients and controls had given their in-
formed written consent.
Sleep questionnaires
The patients were asked to fill in self-administered ques-
tionnaires of sleep quality and daytime sleepiness. Sleep
quality was evaluated by the PSQI which has a timewindow of 4 weeks. It consists of 7 domains with a total
of 19 questions. In each domain a score of 0-3 can be
achieved. The scores of all domains are summarized
(range: 0-21) with higher values indicating poorer sleep
quality ([11]; Additional file 1). Based on prior validations
of the PSQI in psychiatric populations, a value of > 5 is
regarded as evidence for poor sleep quality. Apart from
sleep quality, subjective sleep duration was also extracted
from the answers of the PSQI.
The Epworth Sleepiness Scale (ESS) was used to de-
termine the level of daytime sleepiness. In this ques-
tionnaire, the probability of falling asleep in different
situations (n = 8) has to be rated on a 4-point scale
(0 = ‘never’ to 3 = ‘high probability’). The maximal
score of the ESS is 24 and values of > 10 are considered to
indicate excessive daytime sleepiness ([12]; Additional file
2). The questions of the ESS relate to the “last time” with-
out any further specifications. All patients and controls
who were approached to take part in the study consented
to complete the questionnaires. The results were analyzed
by an investigator blinded to the status of the study partic-
ipants (J.R.).
Data analysis
Data are presented as n/% or mean ± standard error of
the mean as appropriate. ANOVA with Tukey post-hoc
test, student’s t-test, and Chi square test were used for
testing of statistical significance of differences between
the groups in normally distributed parameters. Mann
Whitney U test was performed as non-parametric test.
SPSS 19.0 was used for calculating statistics. A p-value
of < 0.05 was regarded as statistically significant.
Results
Characteristics of patients and controls
The patient characteristics are summarized in Table 1. A
total of 52 IPAH patients and 64 CTEPH patients were
enrolled.
In both groups anthropometric parameters were simi-
lar with a mean age around 60 years, a preponderance of
females and a BMI lying in the upper normal range.
Based on the inclusion criteria of the study, all patients
were in NYHA classes II or III. On an average, they had
only mildly elevated serum BNP levels and relatively well
preserved physical activity (i.e. the average 6MWT
distance was above 350 m). Right heart catheterization
had shown quite severe PH with an average mean PAP >
40 mm Hg in both groups. Except for a moderate impair-
ment of diffusion capacity pulmonary function was nor-
mal. Blood gas analysis yielded mild hypoxemia with
preserved oxygen saturation (i.e. SaO2 above 90%) and
pCO2 levels in the lower normal range (i.e. on an average,
they were about 35 mm Hg in both groups of PH pa-
tients). About 40% of the IPAH and CTEPH patients were
Table 1 Patient characteristics
IPAH CTEPH
Number of patients 52 64
Age (yrs.) 58.2 ± 2.0 62.7 ± 1.7
Females (n/%) 39/75.0 39/60.9
BMI (kg/m2) 26.1 ± 0.9 27.4 ± 0.7
NYHA FC 2.6 ± 0.1 2.6 ± 0.1
BNP (pg/ml) 171 ± 34 120 ± 29
6MWT distance (m) 393 ± 20 375 ± 14
Mean PAP (mm Hg) 45.3 ± 1.9 42.0 ± 1.5
PVR (dyn) 718 ± 62 647 ± 41
CI (l/min/m2) 2.7 ± 0.1 2.3 ± 0.1
CVP (mm Hg) 6.2 ± 0.6 6.2 ± 0.5
PCWP (mm Hg) 8.5 ± 0.5 8.9 ± 0.4
FEV1 (% of pred.) 81.9 ± 3.0 79.0 ± 2.3
IVC (% of pred.) 92.5 ± 2.9 87.7 ± 1.9
FEV1/IVC (% of pred.) 91.4 ± 1.6 92.1 ± 1.6
DLCO (% of pred.) 70.5 ± 2.1 74.6 ± 1.9
pO2 (mm Hg) 68.2 ± 1.6 65.9 ± 1.1
pCO2 (mm Hg) 34.3 ± 0.8 35.7 ± 0.8
LTOT (n / %) 20/38.5 26/40.6
Oral anticoagulation (n/%) 37/71.2 63/98.4
Diuretics (n/%) 43/82.7 47/73.4
No vasodilator therapy (n/%) 11/21.2 16/25.0
Vasodilator monotherapy (n/%) 24/46.2 33/51.6
Vasodilator combination therapy (n/%) 17/32.7 15/23.4
Abbreviations:
BMI: body mass index, BNP : brain natriuretic peptide, CI: cardiac index, CTEPH:
chronic thromboembolic pulmonary hypertension, CVP: central venous
pressure, DLCO: diffusion capacity for carbon monoxide, FEV1: forced
exspiratory volume in one second, IPAH: idiopathic pulmonary arterial
hypertension, IVC: inspiratory vital capacity, LTOT: long-term oxygen therapy,
NYHA FC: New York Heart Association functional class, PAP: pulmonary artery
pressure, PCWP: pulmonary capillary wedge pressure, pO2 / pCO2: partial
pressure of oxygen and carbon dioxide, PVR: pulmonary vascular resistance,
6MWT: six-minute walk test.
Table 2 Sleep characteristics in PH patients vs. controls
IPAH (n=52) CTEPH (n=64) Controls (n=54)
sleep duration (h) 7.1 ± 0.2 7.0 ± 0.2 6.9 ± 0.2
PSQI score 6.1 ± 0.5§ 6.8 ± 0.5§ 4.0 ± 0.4
PSQI score > 5 (n / %) 25/48.1§ 39/60.9§ 10/18.5
ESS score 6.8 ± 0.7 5.7 ± 0.5 5.2 ± 0.4
ESS score > 10 (n / %) 14/26.9§/# 6/9.5 4/7.
Abbreviations:
ESS: Epworth Sleepiness Scale, PSQI: Pittsburgh Sleep Quality Index, for other
abbreviations see Table 1.
§p < 0.01 in comparison to the control group.
#p < 0.01 in comparison to the CTEPH group.
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lants and diuretics and were already treated by pulmonary
vasodilator drugs at the time of study inclusion (either as
monotherapy or combination therapy).
The healthy control group consisted of 54 subjects.
They were matched with the PH patients with regard to
age, gender and BMI (age: 58.9 ± 1.8 yrs, n = 34 females
[63.0%], BMI: 26.4 ± 0.8 kg/m2, p = n.s. in comparison to
the IPAH and CTEPH groups).
Sleep characteristics of PH patients vs. controls
The sleep characteristics of PH patients vs. controls are
shown in Table 2. The average sleep duration was similar
in both groups with approximately 7 hours per night.
Overall, sleep duration was highly variable with significantproportions of patients and controls reporting short or
long sleep duration (i.e. ≤ 6 and ≥ 8 hours per night, data
not shown).
The mean PSQI score was significantly higher in the
PH groups than in the controls. Furthermore, poor sleep
quality (as defined by a PSQI score > 5) was more often
observed in PH. 64 of the 116 patients with PH (i.e.
55.2%) suffered from impaired sleep quality. The average
score of the ESS also tended to be higher in patients
than in controls but these differences did not reach
statistical significance. Daytime sleepiness (i.e. an ESS
score > 10) was observed in 14 out of 52 patients (i.e.
26.9%) with IPAH but in only a few CTEPH patients
and control subjects.
Relation of sleep variables to characteristics of PH patients
The PH patients with vs. without poor sleep quality did
neither differ with regard to anthropometric variables
nor the severity of the disease as reflected by serum
BNP levels and hemodynamics. The same was true for
the use of LTOT and medications (data not shown).
However, those patients who were judged to have im-
paired sleep quality were characterized by significantly
higher average NYHA class (IPAH: 2.6 ± 0.1 vs. 2.3 ± 0.1,
CTEPH: 2.8 ± 0.1 vs. 2.3 ± 0.2; p < 0.01 respectively;
Figure 1a). In addition, poor sleepers had significantly
shorter 6MWT distances (IPAH: 338 ± 23 vs. 441 ± 29 m,
CTEPH: 355 ± 15 vs. 413 ± 26 m; p < 0.05 respectively;
Figure 1b). The PH patients with short/long vs. normal
sleep duration and those with vs. without excessive day-
time sleepiness did not differ with regard to any of the
characteristics investigated (data not shown).
Discussion
The main findings of the present study were that more
than half of the patients with PH suffered from poor
sleep quality and that poor sleepers were characterized
by higher average NYHA class and shorter 6MWT
distances.
Poor sleep quality was frequently encountered in our
PH patients which is in line with a preceding study by
six-minute walk distance
Figure 1 Relation of sleep quality to exercise performance (a)
NYHA functional class and (b) six-minute walk distance. For
abbreviations see Tables 1 and 2. *p < 0.05 in comparison to patients
with a PSQI score≤ 5. **p < 0.01 in comparison to patients with a
PSQI score≤ 5.
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study, we employed more stringent recruitment criteria
(i.e. only IPAH and CTEPH patients) and included a
carefully selected control group of age-, sex- and BMI-
matched healthy volunteers. It is also noteworthy that
we only investigated clinically stable out-patients in
NYHA classes II and III. We presume that poor sleep
quality would have been even more frequent if we had
also enrolled patients who were hospitalized and/or in
NYHA class IV.
An interesting and novel observation was that poor
sleep quality was associated with significantly higher
average NYHA class and shorter 6MWT distances. This
is in contrast to the results of Batal et al. [9] which may
be due to the smaller sample size of this earlier study.
Both NYHA class and 6MWT distance are important
determinants of survival in patients with PH [13-15].
Given the findings of the present study, poor sleep qual-
ity may constitute an adverse prognostic sign in PH just
as it has recently been recognized in patients with
chronic left heart failure [16].
The 6MWT has been widely used as an end point in
drug trials of PH with relatively modest changes
regarded to be clinically significant [17]. The fact that
poor sleepers reached 6MWT distances up to 100 me-
ters shorter than those of good sleepers clearly suggeststhat sleep quality is an important confounder when con-
ducting studies of PH-specific therapy.
Apart from sleep quality we also evaluated daytime
sleepiness and sleep duration in our PH patients. As
already stated, fatigue is one of the leading symptoms of
PH [1]. It should be realized, however, that fatigue and
sleepiness describe two different clinical situations. Fa-
tigue means a feeling of exhaustion leading to limitations
of bodily functions. In contrast, sleepiness is character-
ized by reduced alertness with an uncontrollable propen-
sity to fall asleep. In the study by Batal et al. daytime
sleepiness was observed in 26% of the patients investi-
gated [9]. At least in the IPAH group we found a quite
similar percentage of patients considered to be sleepy.
The average sleep duration was about 7 hours per
night in the PH patients and the controls. Studies per-
formed in the community have found that individual
sleep duration shows a widespread normal distribution
with a peak occurring at 6-8 hours per night [18]. There-
fore, the sleep durations observed in our study can be
considered to lie in the normal range. In contrast to
poor sleep quality, neither daytime sleepiness nor short/
long sleep duration were associated with reduced phys-
ical exercise capacity or any other patient characteristics.
Our study has some possible limitations. First, we did
not perform polysomnography and therefore could not
gain insight into the patients’ sleep architecture, i.e. ob-
jective sleep quality. Second, we did not carry out mul-
tiple sleep latency tests which would have enabled us to
rate the degree of daytime sleepiness of our patients.
Third, it should be realized that the PSQI and ESS have
not yet been validated in PH. Nevertheless, we employed
the cut-off values which have been reported in other pa-
tient populations to separate individuals with vs. without
poor sleep quality/daytime sleepiness to describe our
findings. Fourth, on the basis of our data, it is not pos-
sible to exactly identify the causes of poor sleep quality
in PH.
At least, it does not seem to be related to demographic
variables or the degree of hemodynamic compromise as
these characteristics did not differ between patients with
vs. without impaired sleep quality. One major determin-
ant may be the presence of depression and/or reduced
quality of life as suggested by the data of Batal et al. [9].
Likewise, sleep-related breathing disorders which have
been reported to occur in a considerable proportion of
PH patients may contribute to poor sleep quality [2-6].
We suggest that these issues should be addressed by fu-
ture studies.
A final drawback of the present study may be that we
chose healthy volunteers as a control group. One may
argue that any chronic illness can cause poor sleep qual-
ity and that our findings are nonspecific for PH. Indeed,
this seems to be the case as for example suggested by
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fibrosis [19]. However, the aim of our study was to in-
vestigate if PH patients have poor sleep quality in com-
parison to what is judged to be “normal” and therefore
we included people free from any chronic disease as
controls.
Conclusion
In conclusion, self-reported poor sleep quality is more
common in clinically stable out-patients with PH than in
healthy controls matched for anthropometric variables.
Furthermore, it is related to exercise limitation as
reflected by higher average NYHA class and shorter
6MWT distances. Although more studies are needed
in this area of research, the present findings suggest
that more attention should be paid to sleep-related
symptoms in patients with PH.
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